Investigation reveals MSI-H improves prognosis in endometrial carcinoma cases, indicating implications for treatment with MLH1 methylation status.
Key Points
Patients with mismatch-repair deficiency (MSI-H) have a better prognosis than those with MSS, showing a 25.1% prevalence among 677 patients.
The study found 105 cases of MLH1 promoter methylation, which correlated with more advanced disease but did not show a prognosis difference from non-PHM cases.
Histological analysis demonstrated a higher incidence of G3 histology in the MSI-H group compared to MSS, but better five-year progression-free survival.
Lynch syndrome cases showed lower prevalence of MLH1 hypermethylation, indicating specific genetic implications in endometrial carcinoma.